WHO seeks help from India in latest toxic syrup-deaths case in Cameroon

The alert about Naturcold is the latest of several similar warnings issued in recent months about contaminated cough syrups sold worldwide

World Health Organisation, WHO
Reuters London
2 min read Last Updated : Jul 20 2023 | 10:01 PM IST
The World Health Organization (WHO) has asked the Indian authorities for help in establishing the origins of a contaminated cough syrup that has been linked to children's deaths in Cameroon.
 
The U.N. agency issued a warning on Wednesday about a syrup branded as Naturcold, which was sold in Cameroon and linked by authorities there with at least six children's' deaths. The syrup contained extremely high levels of the toxic contaminant diethylene glycol, the WHO said.

The manufacturer of Naturcold is listed on the packet as Fraken International (England), but the UK regulator told WHO that no such company exists.

The WHO wrote to India's regulator as the alert was issued on Wednesday, asking for help in reaching Indian companies that may be involved, a spokesperson told Reuters. Other countries have also been contacted, she said.

The alert about Naturcold is the latest of several similar warnings issued in recent months about contaminated cough syrups sold worldwide.

In 2022, the medicines were linked to the deaths of more than 300 children in Gambia, Uzbekistan and Indonesia. Another alert earlier this year also said contaminated medicines had been found in the Marshall Islands and Micronesia, but no deaths have been reported there. The WHO has said the threat is ongoing.

All of the syrups are made by different manufacturers, although in three of the four incidents, they are Indian-made.
The deaths in Indonesia were linked to syrups made domestically.

The WHO said this pattern meant that working with India was a high priority in finding out more about the incident in Cameroon. It previously said efforts to find out more about the cough syrup incidents and the supply chains involved had been stymied by a lack of information from the Indian authorities and drugmakers.

Officials in India and Cameroon did not immediately respond to requests for comment.

(Reporting by Jennifer Rigby in London; Additional reporting by Krishna N.Das in New Delhi and Amindeh Blaise Atabong; Editing by David Holmes)
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :World Health OrganizationCough syrupCameroonPharma sector

First Published: Jul 20 2023 | 10:01 PM IST

Next Story